The Conversation (0)
RepliCel Life Sciences showcased the prototypes of RCI-02, which will be presented to end users and licensing partners.
RepliCel Life Sciences (OTCQB:REPCF; TSXV:RP) showcased the prototypes of RCI-02, which will be presented to end users and licensing partners.
As quoted in the press release:
With functioning prototypes in-hand, RepliCel is now engaging with key opinion leaders and clinical dermatologists to solicit feedback critically important to aligning successful early adoption of the device, design clinical studies demonstrating its advantages in select applications, and position the Company for an anticipated successful launch of an approved next-generation dermal injector in the European market next year.
“As a practicing dermatologist and a co-founder of RepliCel, I am thrilled to see the functioning prototypes. We are excited to begin exploring the clinical applications of this device with our global network of dermatology experts,” stated RepliCel Chief Medical Officer, Dr. Rolf Hoffman, MD.
Click here to read the full press release.
Source: www.newswire.ca
